The influence of SARS-CoV-2 vaccination on post-operative outcomes in microsurgery patients.

Microsurgery 2022 Vol.42(7) p. 685-695

Taghioff SM, Slavin BR, Narasimman M, Samaha G, Samaha M, Holton T, Singh D

관련 도메인

Abstract

[BACKGROUND] The healthcare industry's efforts to immunize the global community against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been unprecedented. Given the fast-tracking of the novel vaccine, its short- and long-term medical implications remain largely to-be-determined in most patient populations. This study aims to analyze 90-day post-operative outcomes in microsurgical patients, who have received or not received SARS-CoV-2-vaccination, using a continuously updated federated electronic medical record network (TriNetX Inc, Cambridge, MA).

[METHODS] After screening 70 million de-identified records, 16,799 microsurgery patients aged 18-99 meeting medical coding criteria were allocated into two cohorts. Cohort One received SARS-CoV-2-vaccination prior to undergoing microsurgery whereas Cohort Two did not. Two equally sized cohorts, totaling 818 patients were created after propensity score matching for characteristics including: age, race, ethnicity, smoking, hypertension, heart disease, diabetes, obesity, chronic obstructive pulmonary disease, and history of SARS-CoV-2 exposure. Postoperative outcomes within 30-, 60-, and 90-days of microsurgery were analyzed.

[RESULTS] Patients who were SARS-CoV-2-immunized experienced significantly lower (p < .01) surgical site infections (Absolute Risk Reduction (ARR)[95%CI]) = (3.79%-5.36% [0.84-8.54]) ICU admission (9.47%-9.82%[5.45-13.88]), generalized infections (7.68%-9.92%[3.15-14.64]), and hospitalizations (28.48%-32.57%[20.99-40.13]) within 30-, 60-, and 90-days of microsurgery. Additionally, SARS-CoV-2-vaccinated patients also experienced significantly less flap failure (2.49%[0.97-4.02]) and death (2.46%[0.96-3.97]) within 30- and 60-days post-operatively.

[CONCLUSION] Our analysis examines the potential protective effect of SARS-CoV-2-vaccination in microsurgical patients. Limitations include the retrospective nature of this analysis and the inherent reliance on medical coding. Future prospective studies are warranted to better understand if in fact pre-operative SARS-CoV-2-vaccination has the potential to protect against post-operative microsurgery outcomes.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 microsurgery 미세수술 dict 6
시술 flap 피판재건술 dict 1
해부 heart scispacy 1
해부 pulmonary scispacy 1
약물 [BACKGROUND] The scispacy 1
약물 30- scispacy 1
약물 60-days scispacy 1
질환 acute respiratory syndrome C0035222
Respiratory Distress Syndrome, Adult
scispacy 1
질환 hypertension C0020538
Hypertensive disease
scispacy 1
질환 heart disease C0018799
Heart Diseases
scispacy 1
질환 diabetes C0011847
Diabetes
scispacy 1
질환 obesity C0028754
Obesity
scispacy 1
질환 chronic obstructive pulmonary disease C0024117
Chronic Obstructive Airway Disease
scispacy 1
질환 infections C0851162
Infections of musculoskeletal system
scispacy 1
질환 death C0011065
Cessation of life
scispacy 1
기타 patients scispacy 1
기타 patient scispacy 1

MeSH Terms

COVID-19; COVID-19 Vaccines; Humans; Microsurgery; Retrospective Studies; SARS-CoV-2; Vaccination

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문